Edition:
United States

Profile: Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

2.16USD
22 Sep 2017
Change (% chg)

$-0.02 (-0.92%)
Prev Close
$2.18
Open
$2.17
Day's High
$2.19
Day's Low
$2.14
Volume
130,396
Avg. Vol
235,738
52-wk High
$3.14
52-wk Low
$1.81

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

Company Address

Geron Corp

149 Commonwealth Dr Ste 2070
MENLO PARK   CA   94025-1133
P: +1650.4737700
F: +1302.6365454

Company Web Links